December 27,Innovent BioAnnounced that it has reached an agreement withSanegene Bio(SANEGENEBIO) has reached a strategic cooperation agreement to jointly develop the small nucleic acid (siRNA) candidate drug SGB-3908 targeting Angiotensinogen (AGT) for the treatment of hypertension. Innovent Bio has obtained the exclusive option for the future development, production, and commercialization of this drug.
SGB-3908 is a proprietary siRNA drug developed by SANEGENEBIO based on the company's proprietary small nucleic acid drug development platform LEAD™ (Ligand and Enhancer Assisted Delivery) and is currently in the IND application preparation stage.Phase.According to the cooperation agreement, the two parties will jointly advance the development of SGB-3908 to a certain stage. Meanwhile, Innovent Bio will obtain an exclusive option and can pay the exercise fee in the future to gain exclusive rights for the development, production, and commercialization of SGB-3908 across different regions globally.After the exercise of rights by Innovent Bio, SANEGENEBIO will also be entitled to subsequent R&D milestone payments and sales milestone payments, as well as tiered royalties based on net sales after commercialization.AGT is the most upstream precursor of the renin-angiotensin-aldosterone system (RAAS). Its role in blood pressure (BP) regulation has been confirmed, and inhibiting AGT is recognized to have an antihypertensive effect. SGB-3908 can inhibit the synthesis of AGT in the liver, potentially leading to a sustained reduction in AGT protein, further resulting in decreased levels of angiotensin (Ang) II, ultimately causing vasodilation and reduced blood pressure.
SGB-3908 Mechanism of Action
The strategic cooperation with SANEGENEBIO to develop siRNA drugs for the treatment of hypertension will further expand Innovent Bio'sMetabolism and CardiovascularTube（CVM）Strategic layout in the field, forming a more complete product matrix and long-term competitive advantage.Since strategically laying out in the CVM field with next-generation innovative therapies a few years ago, Innovent Bio has gradually entered the harvest period of its high-value pipeline. Xinbile® (PCSK9 monoclonal antibody) has been approved for marketing to treat hyperlipidemia. Mashudu peptide (GLP-1R/GCGR) for treating diabetes and obesity is about to submit its first NDA. IBI311 (IGF-1R monoclonal antibody) for treating thyroid eye disease has entered Phase III clinical trials. IBI128 (XOI inhibitor) for treating hyperuricemia is already in Phase III clinical trials overseas.The potential of RNAi therapy in the field of chronic diseases is gradually emerging, and pharmaceutical giants such as Novartis, Roche, and Novo Nordisk have all incorporated this therapy into their pipelines.Novartis, as a pioneer in the RNAi field, has entered the commercialization process. Inclisiran, an siRNA drug targeting PCSK9, achieved $142 million in sales revenue in H1 2023, with an increase of 294%.Targeting AGTThe clinical potential of siRNA drugs has also been preliminarily confirmed in clinical trials, Roche$2.8 Billion fromAlnylam PharmaceuticalsIntroducedThe long-acting antihypertensive drug Zilebesiran has achieved positive results in Phase II studies, with a dosing frequency of just one subcutaneous injection every six months.Innovent Bio, Qilu, Hengrui, Junshi, and Zhengdatianqing, among other leading pharmaceutical companies in China, are also poised to compete, with their siRNA new drugs awaiting clinical trials.The content of the article is for reference only and does not constitute investment advice. Investors who take action based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints presented, and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use it solely as a reference and assume full responsibility for their actions. The various articles published by this public account aim to share information; if there is any infringement, please contact us, and we will delete the content.
Booths for the Class of 2024 are now available for booking!
(Sponsorship forms include but are not limited toSpeaking slots, exhibition booths, color pages in the conference proceedings, dinner sponsorship, promotional materials for the conference, etc.)
Scan to consult immediately!
Contact Number: 17521760400 (Same as WeChat)
Email: marketing@truesaw.com
Click here to "Read More" for further consultation!
